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Abstract: The aim of this project was to study the influence of microneedles on
transdermal delivery of amantadine hydrochloride and pramipexole dihydrochloride
across porcine ear skin in vitro. Microchannel visualization studies were carried out and
characterization of the microchannel depth was performed using confocal laser scanning
microscopy (CLSM) to demonstrate microchannel formation following microneedle roller
application. We also report, for the first time, the use of TA.XT Plus Texture Analyzer to
characterize burst force in pig skin for transdermal drug delivery experiments. This is the
force required to rupture pig skin. The mean passive flux of amantadine hydrochloride,
determined using a developed LC–MS/MS technique, was 22.38 ± 4.73 µg/cm2/h, while
the mean flux following the use of a stainless steel microneedle roller was 49.04 ±
19.77 µg/cm2/h. The mean passive flux of pramipexole dihydrochloride was 134.83 ±
13.66 µg/cm2/h, while the flux following the use of a stainless steel microneedle roller was
134.04 ± 0.98 µg/cm2/h. For both drugs, the difference in flux values following the use of
solid stainless steel microneedle roller was not statistically significantly (p > 0.05).
Statistical analysis was carried out using the Mann–Whitney Rank sum test.
Keywords: transdermal; solid microneedles; microneedle roller; percutaneous flux; burst force
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1. Introduction
Parkinson’s Disease (PD) is a disabling, neurodegenerative disorder with no current treatment
option to alter the progression of the disease [1,2]. In the United States, PD affects nearly 1.5 million
Americans, and according to a recent study, approximately 50,000 new cases are diagnosed each year,
and this number is expected to increase substantially as the median age of the population continues to
rise [2–5].
Ultimately, patients suffering from PD exhibit progressive decline in motor function, resulting in
significant disability [1,6]. Cardinal symptoms of the disease include resting tremor, bradykinesia,
rigidity, and postural instability [7]. Although there is still no cure for PD, various symptomatic
therapy options are available in the form of oral medications, surgery, and an FDA-approved rotigotine
transdermal patch called Neupro®; however, its use focuses on treating idiopathic and early stage
PD [1,8]. Available oral therapies include levodopa, dopamine agonists, monoamine oxidase type B
inhibitors (MAO-B inhibitors), catechol-O-methyltransferase inhibitors (COMT-Inhibitors), amantadine,
and anticholinergic agents [1,9–12].
In a study by the American Academy of Neurology, amantadine, dopamine agonists, and other
common antiparkinsonian agents were examined. This study found that amantadine hydrochloride
relieved PD symptoms by acting on certain postsynaptic receptors in the striatum, whereas dopamine
agonists bind to and activate dopamine receptors [7,12]. In the literature, amantadine has shown to be
effective and is mostly utilized to treat peak-dose levodopa-induced dyskinesia (LID) in patients with
advanced stage PD [13].
It has been suggested that non-ergot dopamine agonists like pramipexole dihydrochloride may
reduce the duration of “off-time” episodes [12].
Chase and Oh have hypothesized that nonphysiologic stimulation of striatal dopaminergic receptors
may trigger adaptive responses in the basal ganglia, which contribute to the appearance of parkinsonian
symptoms and later to the dyskinesias [14]. Our rationale in developing transdermal formulations for
pramipexole is that a steady zero-order drug input is capable of reducing peak-trough variations and
this leads to continuous stimulation of dopamine receptors [15]. This models normal physiological
conditions in healthy individuals and from a therapeutic perspective less complications [15].
Transdermal drug delivery will lead to a more stable plasma concentration, reduced side effects and
better patient compliance. Our long term goal is the development of a transdermal system for the
delivery of pramipexole and amantadine.
It is important to expand the scope of transdermal drug delivery options as an alternative form of
administration. Transdermal drug delivery has expanded greatly in the last decade as an exciting
potential therapy approach that provides considerable benefits. For instance, this route of administration
is capable of providing drug delivery at a controlled and constant rate while also being non-invasive
and simple to use, which would be advantageous for patients that suffer from advanced stage PD.
Microneedle-facilitated transdermal delivery has the potential of increasing skin permeability for
many compounds that normally do not penetrate the stratum corneum (SC), which is the outermost
layer of the skin and the major barrier for transdermal drug delivery [16–18]. As an alternative delivery
route, microneedle-assisted transdermal drug delivery is minimally invasive and capable of providing
sustained drug release, thus reducing dosing frequency. When administered to the skin, these micron-
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sized needles do not reach the nerve fibers located within the dermis layer of the skin, making this
approach a painless route of administration [19]. Additionally, a microneedle delivery system can be
self-administered, and the ease and convenience of this application system could potentially improve
patient adherence to medication therapy, which is especially important for patients suffering from
advanced-stage PD, since improving quality of life is of great significance [20].
Pramipexole is a cationic drug with a net positive charge at physiological pH (pKa 5.0 and 9.6) and
an octanolphosphate buffer (pH 7.4) partition coefficient of 0.135 [21]. It has a molecular weight of
284.25 g/mol [22] and a pharmacokinetic half-life of 6–8 h [23]. A transdermal delivery system for
pramipexole might provide benefits compared to oral dosage forms. Apart from the pharmacokinetic
aspects, adherence to therapy is an issue for elderly patients including those that suffer from PD. Some
elderly patients simply forget to take their medications, especially those on multiple medications.
Amantadine has a molecular weight of 187.71 g/mol and a partition coefficient of 2.44 [24]. The
pharmacokinetic half-life of the drug is 10 h [25]. Patience compliance will be greatly improved if
amantadine is formulated into a transdermal patch.
The aim of this study was to investigate the influence of microneedles on transdermal delivery of
amantadine hydrochloride and pramipexole dihydrochloride across porcine ear skin in vitro. Stainless
steel microneedle rollers were utilized to create microchannels in the SC to assist with the delivery of
amantadine hydrochloride and pramipexole dihydrochloride across porcine skin.
2. Materials and Methods
2.1. Materials
Stainless steel microneedle rollers (500 μm) were purchased from Pearl Enterprises LLC.
(Lakewood, NJ, USA) Amantadine hydrochloride, pramipexole dihydrochloride, and 0.1 M isotonic
phosphate buffered saline (PBS) were purchased from Sigma–Aldrich Co. (St. Louis, MO, USA).
Amantadine hydrochloride and pramipexole dihydrochloride were reconstituted using PBS. The water was
processed using NanoPure Infinity Ultrapure water purification system (Barnstead, Dubuque, IA, USA).
2.2. Methods
2.2.1. Skin Preparation
Experiments were approved by the Institutional Animal Care and Use Committee (IACUC) and
Institutional Biosafety Committee (IBC) of Touro University, Mare Island-Vallejo, CA, USA. Frozen
porcine ears were obtained from Animal Technologies, Tyler, TX, USA. Skin pieces were thawed at
ambient temperatures and carefully shaved using an electric clipper (Wahl, Sterling, IL, USA). Full
thickness skin was prepared by removing the subcutaneous fat from the underlying cartilage. The
average thickness of the skin membrane was measured with a Digimatic Micrometer (Mitutoyo,
Tokyo, Japan). Skin samples were maintained at −20 °C for storage. Prior to experiments, the skin
samples were thawed at room temperature before use.

Pharmaceutics 2015, 7

382

2.2.2. In Vitro Diffusion Studies
In vitro permeation experiments were conducted using a six-celled, static, vertical Franz diffusion
cell system (PermeGear, Hellertown, PA, USA). Each cell contained a top donor compartment and a
lower receptor compartment with a magnetic stirrer, sampling port, and water jacket maintained at
37 °C to simulate normal body temperature by Thermo Haake DC10-P5/U heating circulator bath
(ThermoFisher Scientific, Waltham, MA, USA). The receptor compartment diffusion area was
1.77 cm2 with a volume capacity of 12 mL filled with PBS. Skin samples obtained from different
pigs were placed between the upper donor chamber and lower receiver chamber of the vertical Franz
diffusion cells, which were sealed using high-vacuum grease (Dow Corning, Midland, MA, USA) and
a metal clamp. Solid microneedle rollers were used to created microchannels in porcine skin.
Full thickness microneedle-treated porcine skins were mounted on three-receptor compartments and
untreated porcine skins were placed on the remaining three-receptor compartments to serve as controls,
and diffusion experiments for the two drugs were replicated six times (n = 6). The microneedle roller
was applied fifteen times to each skin sample to increase the number of microconduits for enhanced
transdermal drug delivery. Before each microneedle application, the skin samples were rotated 90° and
the microneedles were applied with a force of 9.07 kg for ~1 min per application. Each experiment was
performed using 1 mL of either amantadine (~50 mg/mL) or pramipexole (~1 mg/mL), which was
loaded onto the skin samples via the donor compartment and covered with parafilm and aluminum foil
to reduce evaporation. The sampling ports were also covered with parafilm to further reduce
evaporation. Aliquots of 1 mL were removed from the sampling port at the interval of 2 h for a 12-h
period and placed into vials for high performance liquid chromatography-mass spectrometry (HPLC–MS).
Receptor chambers were replenished with an equal volume of fresh, pre-warmed PBS maintained at
37 °C. All samples were stored at 4 °C until analysis by LC–MS. The cumulative amount of each drug
permeating the excised full thickness porcine skin was plotted as a function of time. The slope and
intercept of the linear portion were derived by linear regression analysis. Steady state flux was
calculated from the linear portion of the cumulative amount versus time curve. The cumulative amount
of each drug permeated (Qs, μg/cm2) for 12 h was also calculated.
2.2.3. High-Performance Liquid Chromatography–Mass Spectrometry Analysis (HPLC–MS)
HPLC–MS analysis was performed using an Agilent series 1200 HPLC with diode-array and
Agilent 6320 Ion Trap mass spectrometer detectors (Agilent Technologies, Palo Alto, CA, USA).
Chromatographic separation was carried out on the reverse-phase Agilent Zorbax Eclipse Plus C18
(100 mm × 2.1 mm, 3.5 microns) analytical column, which was protected by a guard column with the
same stationary phase (12.5 mm × 4.6 mm, 5 microns) (Agilent Technologies, Palo Alto, CA, USA).
The column temperature was set at 40 °C, and the autosampler temperature was set at 4 °C. The
mobile phase consisted of 0.1% formic acid in water (solvent A), and 0.1% formic acid in methanol
(solvent B). The solvent gradient was performed at 0.4 mL/min with an initial condition of 5% of
mobile phase B. Mobile phase B was increased to 95% at 2 min and held at 95% B until 6 min at
which Mobile phase B was then reduced to 5% at 7 min. A post-run time of 2 min for mobile phase
equilibration was used after each sample run. Calibration curve standards were freshly prepared in PBS
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buffer solution. The MS data were collected in positive electro spray ionization tandem mass
spectrometry (ESI MS/MS) mode. Nebulizer temperature was 350 °C, nebulizer pressure was 50 psi,
and the drying gas flow rate was 10.0 L/min. Compounds were quantified in positive ESI MS/MS
mode by quantifying the specific product ion. A UV spectrum was only collected for pramipexole
dihydrochloride at the wavelength of 263 nm because the structure of amantadine hydrochloride is not
conjugated; therefore, mass spectrometric detection was used. For amantadine hydrochloride, ion
transitions m/z was 152.0→135.1 and for pramipexole dihydrochloride, ion transitions m/z was
212→153.
2.2.4. Visualization of Microchannels
Microchannel imaging studies were conducted at the Comparative Pathology Lab of the University
of California, Davis. Porcine skin samples were treated with a 500 μm long microneedle roller for
~1 min and then stained with a margin marking dye (American MasterTech Scientific Inc., Lodi, CA,
USA). Following treatment, skin samples were immediately rinsed with saline to remove excessive
dye. As the control, untreated porcine skin samples were similarly stained with margin marking dye for
~1 min and immediately rinsed with saline. Pictures of the treated and untreated skin samples were
collected using a digital camera (Canon, Melville, NY, USA).
2.2.5. Characterization of Microchannel Depth by Confocal Laser Scanning Microscopy (CLSM)
CLSM was performed at the Cellular and Molecular Imaging Lab of the University of California,
Davis to characterize the depth of the created microchannels. Excised full thickness porcine skin was
treated with a microneedle roller device. The porated site was treated with 200 μL of a fluorescent dye,
Alexafluor 488 (Life Technologies, Eugene, OR, USA) for ~1 min, after which the site was blotted
with kimwipes to remove excess dye. Samples of microneedle treated porcine skin were mounted onto
Tissue-Tek Cryomold (Sakura Finetek Inc., Torrance, CA, USA) and covered with OCT embedding
media (Sakura Finetek Inc., Torrance, CA, USA) before freezing in dry ice storage at −80 °C. Skin
samples were maintained on dry ice before cry-sectioning using a Leica CM1950 Cryostat (Leica
Biosystems, Buffalo Grove, IL, USA). Samples were cry-sectioned to 10 μm-thick vertical sections
and mounted onto glass slides. Transmission images of the skin samples were examined and recorded
using a Leica TCS LSI laser scanning confocal microscope at 5× magnification. Excitation was carried
out at 488 nm and emission at 520 nm. X-Z sectioning was performed to detect depth of dye
fluorescent penetration. The frame size was set to 1024 × 1024 pixels, and gain and offset were
maximized to enhance contrast of images. Depth of the microchannels was estimated indirectly based
on migration of the Alexafluor 488 down the microchannel to indicate dye permeation.
2.2.6. Burst Strength
Burst strength of skin was evaluated using a TA.XT Plus Texture Analyzer (Texture Technologies,
Hamilton, MA, USA) to measure the force required to rupture the skin. The burst strength study was
carried out using a burst rig which uses a 5 mm spherical stainless steel ball probe attached to a probe
adapter connected to the load cell (50 kg maximum load).
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2.2.7. Data Analysis
Flux values were calculated using the steady-state portion of the cumulative amount versus time
curves. Six replicates were used for the study. Drug concentration was corrected for sampling effects
according to Equation 1, proposed by Hayton et al and used by other investigators [26–28].
=

(1)

is the corrected concentration and
represents the measured concentration in
In this equation,
the nth sample.
is the total volume of the receiver fluid (12 mL) and
represents the volume of
and
are corrected and measured
sample withdrawn from the receiver fluid (1 mL). While
concentration, respectively in (n − 1)th sample.
2.2.8. Statistical Analysis
Statistical analysis was performed using Sigmastat (Systat Software, San Jose, CA, USA).
Mann–Whitney Rank sum test was carried out to determine statistical significance. Mean of replicate
measurements (n = 6) with corresponding standard deviation was used to plot the graphs.
3. Results
3.1. Characterization of Microneedle Array and Microneedle Roller
When microneedles are applied to the surface of the skin they disrupt the barrier of the SC and
create microchannels, resulting in increased drug penetration [16,29]. A stainless steel microneedle
roller was used in this study to deliver the antiparkinsonian agents amantadine hydrochloride and
pramipexole dihydrochloride across porcine skin. The microneedle roller contains microneedles
protruding from a cylindrical surface measuring 500 μm in length per microneedle with a density of 192
needles (Figure 1). Following microneedles application, microchannels were visualized, as shown in
Figure 2A, and the microchannel depth was characterized, as shown in Figure 3B.

Figure 1. Stainless steel microneedle roller, density of 192 microneedles and 500 μm in
length per microneedle.
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Figure 2. Microchannel visualization using margin marking dye. (A) Porcine skin treated
with microneedle roller. (B) Non-treated porcine skin as the control.

Figure 3. Representative depth of a single microchannel by confocal laser scanning
microscopy (CLSM). (A) Untreated porcine skin. (B) Microneedle treated porcine skin
showing a microchannel depth of 255 μm.
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3.2. Visualization of Microchannels
After application of the microneedle roller across the skin surface, the created microchannels can be
visualized. Figure 2A is a picture of full thickness porcine skin stained with margin marking dye
following treatment with one pass of the microneedle roller. The areas of the skin that were
disrupted by the microneedles took up the dye identifying the created microchannels immediately after
application of the solid microneedle roller. The portion of the skin surrounding the microchannels
maintained normal structure and intact stratum corneum. Figure 2A shows the pattern of the created
microchannels aligned symmetrically, mirroring the pattern of the microneedle roller. A control was
employed to demonstrate that the microchannels on the surface of the skin are due to the microneedles
alone (Figure 2B).
3.3. Characterization of Microchannel Depth by Confocal Laser Scanning Microscopy (CLSM)
Porcine skin samples were imaged and recorded to characterize the depth of the microchannel
created by the microneedle roller from the surface of the skin using CLSM (Figure 3A,B). The skin
samples were treated with Alexafluor 488 and the binding of the Alexafluor fluorescent particle along
the microchannels indicates the depth of the created microchannel, which resulted in a mean depth of
319.50 ± 71.05 μm (n = 4). Figure 3 is a representative image of a single microchannel displaying the
microchannel depth of 255 μm. In contrast, the non-disrupted skin sample served as the control, and
results revealed no created microchannel (Figure 3A). It is important to note that microchannel depth is
directly influenced by various factors such as the elasticity of the skin, application force [30].
3.4. Burst Strength
The skin has both elastic and viscous properties and must be strong and ductile to provide
protection to the body and prevent foreign substances from entering through the skin.
In this study, for the first time, a Texture Analyzer was used to test the skin to measure the burst force
from porcine skin samples. Burst force strength indicates that the skin is flexible and, at the same time,
rigid enough to prevent the deformation from foreign objects and agents that are imposed upon the
stratum corneum (SC) surface. Table 1 shows that the results of burst strength and distance to burst
porcine ear skin, which indicates that the skin samples are slightly elastic and rupture with an average
force of 187.5 N at a distance of 7.76 mm.
Table 1. Burst force required to rupture porcine skin (n = 6).
Initial
Gradient (N/s)

Mid Gradient
(N/s)

Final Gradient
(N/s)

Work to Burst
Skin (N/s)

Burst Force
(N)

Distance to
Burst (mm)

13.75 ± 2.11

43.98 ± 8.17

62.14 ± 11.54

341.24 ± 42.44

187.54 ± 19.38

7.77 ± 0.63

3.5. In Vitro Diffusion Studies
An in vitro diffusion study was carried out to identify the influence of solid microneedles on the
transcutaneous absorption of amantadine hydrochloride and pramipexole dihydrochloride. This study
was performed using porcine ear skin as a representative model of human epidermal membrane [31,32].
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In our experiments, the mean porcine skin thickness was 761 ± 0.18 µm. LC–MS was used to
determine the concentration of the drug in the samples and flux values were determined for both
agents using the slope of the steady-state portion of the cumulative amount versus time curves and
concentration was corrected for sampling effects according to Equation 1. Table 2 shows a comparison
of the final cumulative amounts of both drugs after 12 h (Qs) following microneedle treatment to
passive permeation. A microneedle roller was applied to full thickness pig ear skin at the beginning of
experiments, and the amounts of amantadine and pramipexole delivered after 12 h are shown in
Table 2 (589.26 and 1583.43 µg/cm2 respectively). Table 3 shows a comparison of transdermal flux for
both drugs. The passive transdermal flux for amantadine hydrochloride was 22.38 ± 4.73 µg/cm2/h,
while microneedle-facilitated flux was 49.04 ± 19.77 µg/cm2/h (Figure 4). For pramipexole, passive
transdermal flux was 134.83 ± 13.66 µg/cm2/h, while microneedle-facilitated flux was 134.04 ± 0.98
µg/cm2/h. The percutaneous flux of each drug was plotted as a function of time (Figure 5).
Table 2. Cumulative amount after 12 h (Qs, μg/cm2 ± SD) of amantadine and pramipexole
following treatment with a 500 μm long microneedle roller. Passive flux values served as
controls (n = 6).
Amantadine Qs Passive (Control) Qs (μg/cm2) Microneedle Qs (μg/cm2)
Mean
267.65 ± 14.07
589.26 ± 23.13
2
Pramipexole Qs Passive (Control) Qs (μg/cm ) Microneedle Qs (μg/cm2)
Mean
1607.86 ± 35.77
1583.43 ± 72.99

Table 3. Transdermal flux (μg/cm2/h ± SD) of amantadine and pramipexole following
treatment with a 500 μm long microneedle roller. Passive flux values served as controls
(n = 6).
Amantadine Flux Passive (Control) Flux (μg/cm2) Microneedle Flux (μg/cm2)
Mean
22.38 ± 4.73
49.04 ± 19.77
2
Pramipexole Flux Passive (Control) Flux (μg/cm ) Microneedle Flux (μg/cm2)
Mean
134.83 ± 13.66
134.04 ± 0.98
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Figure 4. In vitro transdermal permeation of passive and microneedle-facilitated amantadine
hydrochloride after microneedle roller application across porcine ear skin (500 μm length,
540 needles per square centimeter density).
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Figure 5. In vitro transdermal permeation of passive and microneedle-facilitated
pramipexole dihydrochloride after microneedle roller application across porcine ear skin
(500 μm length, 540 per square centimeter density).
4. Discussion
The skin is a composite material consisting of a collagen-rich fibrous network embedded in a
proteoglycan-rich matrix [33]. The main fibrous constituents, collagen and elastin, provide structural
stiffness and elasticity to the skin while the ground matrix is responsible for its viscous nature at low
loads [33]. Effectiveness of microneedle-mediated transdermal drug delivery depends on a number of

Pharmaceutics 2015, 7

389

factors including the mechanical properties of the skin. The inherent elasticity and irregular surface of
the skin is a challenge for reproducibility of microneedle flux values [34]. In this paper we seek, for
the first time, to introduce burst strength as a parameter that can be used to characterize pig skin in
transdermal drug delivery experiments. Burst strength is the pressure at which pig skin will burst. This
parameter measures resistance to rupture and is a function of tensile strength as well as extensibility of
the skin. It is thus a composite strength property that is affected by other properties of the skin,
principally tensile strength and stretch. It can be determined by using a TAXT-analyzer and is
expressed in Newtons (N).
The focus of our study was on transdermal delivery of therapeutic agents used in the management
of PD. The underlying pathology of PD is due to the gradual loss of dopaminergic neurons in the
substantia nigra pars compacta of the basal ganglia [35]. Several studies speculate that genetics,
environmental toxins, and several pathological processes such as oxidative stress, apoptosis and
mitochondrial DNA defects might be involved in the pathway leading to the degeneration of dopamine
neurons; however, there is no definitive proof that any one of these is critically involved, which leaves
the cause of PD largely unknown [4,36].
Levodopa is the most potent oral medication for the symptomatic treatment of PD [1,37–39].
However, levodopa is not commonly used as initial therapy in the treatment of PD due to its side
effects. This phenomenon was first reported by Cotzias et al., followed by subsequent studies showing
that long-term treatment with levodopa becomes less effective in eliminating motor symptoms and
produced levodopa-induced dyskinesia (LID), a hyperkinetic side effect of levodopa therapy in PD
patients [13,40–43]. Furthermore, later studies have also shown that early use of levodopa may
predispose patients to develop long-term motor complications, such as dyskinesia, dystonia, and these
symptoms may prematurely return or worsen before the next dose is due, which is called “wearing
off” [13,44,45]. These complications has been reported especially in young-onset PD patients [46].
This growing recognition of the complexity involved in long-term management and pulsatile
stimulation of dopamine receptors that lead to motor fluctuations that often develop and compromise
the effectiveness of long-term levodopa administration in PD patients emphasizes the need for
improved therapy and potential alternative drug delivery options [45]. However, developing a drug to
be delivered across the skin for the treatment of advanced-stage PD is challenging.
Successful transdermal absorption requires a drug to cross the stratum corneum barrier (SC), which
is the outermost layer of the epidermis, and ultimately enter the systemic circulation [47–49]. The SC
contains a unique structure comprised of a lipid-rich matrix embedded with corneocytes, which are
dead, partially desiccated, and keratinized epidermal cells [17]. Although the SC layer is only about
10–15 μm thick, and only accounts for 0.1 mm of the skin’s 1.5 mm thickness, this unique layer is the
major barrier against drug permeation [17,48,50]. The structure of the SC can be explained in terms of
the “brick and mortar” model, in which the corneocytes represent the bricks, and the intercellular lipid
matrix acts as the mortar [19,51]. Due to the limiting parameters of the SC, there are currently only
about 40 transdermal products on the market containing 19 active ingredients [17,19].
Amantadine is used in the treatment of tremors as well as dyskinesia, but its mechanism of action is
not clearly elucidated [7,11,15,16]. Several literature sources report that amantadine is a
weak noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist and suggest that
amantadine acts by blocking NMDA glutamate and acetylcholine receptors thereby promoting the
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release of dopamine, while others suggest that the mechanism is unknown [3,17]. Regardless of the
mechanism of action, amantadine has been shown to be effective and is mostly utilized to treat peakdose LID in patients with advanced stage PD [13]. On the other hand, pramipexole dihydrochloride is
a dopamine agonist and is effective in reducing the duration of “off-time” episodes [12,38,39].
Ghosh and co-authors report that normal healing processes of the skin result in the resealing of
micropores formed after application of microneedles within 48–72 h under occlusion. Therefore, a
drug can be delivered across microneedle-treated skin for 3 days under occlusion [52]. Although we
did not investigate the size of microchannels in our study, there is a report in the literature which
showed that the mean diameter of microconduits created by a microneedle roller at the surface of the
skin was approximately 70 μm [30]. In that project, the authors combined confocal microscopy with
micron-sized fluorescent particles.
Based on our results, the stainless steel microneedle roller was capable of creating microchannels in
the SC as demonstrated from the microchannel visualization studies and confocal images, but there
was no statistically significant increase in percutaneous absorption of amantadine hydrochloride or
pramipexole dihydrochloride across porcine skin. Although there was a 1.57-fold increase in mean
flux for amantadine hydrochloride, the difference in flux following the use of solid stainless steel
microneedle roller was not statistically significant (p < 0.05). The difference between passive and
microneedle-facilitated fluxes of pramipexole was also not statistically significant (p < 0.05).
Several factors can cause lack of transdermal flux enhancement, which we witnessed in this project.
The physiochemical properties of a drug can influence the rate of transdermal drug penetration.
The physiochemical properties of a drug include: molecular weight, diffusion coefficient, drug
concentration, melting point, pH, and charge [17,53,54].
For a drug molecule to passively diffuse across the SC, it must have a low molecular weight,
typically less than 500 Daltons. Additionally, since inside the skin is an aqueous environment and the
skin is made of a lipid-rich bilayer, it is important that the drug molecule possess both lipid and
aqueous solubility that is suitable for percutaneous absorption. Thus, the ideal drug compound would
possess an aqueous solubility of greater than 1 mg/mL and lipophilicity between 1–3 [17,55].
However, these properties would likely not have influenced percutaneous absorption of our
compounds of interest, as both substances are relatively small compounds with appropriate water
solubility and lipophilicity that are theoretically suitable for passive diffusion across the SC. As
mentioned, the molecular weights, water solubility, and lipophilicity of amantadine hydrochloride and
pramipexole dihydrochloride are 187.71 Da, 50 mg/mL, with a logP of 2.4 and 284.25 Da, >20 mg/mL,
with a logP of 1.2 respectively.
Low diffusion coefficient is a possible explanation for the low flux values observed in this study.
Since passive drug absorption through the skin is governed by diffusion, the drug molecule of interest
must move according to the concentration gradient from high to low [55]. Commercially, amantadine
hydrochloride is available as 100 mg oral capsule or tablet often prescribed at twice a day as
monotherapy and may increase to 400 mg/day in divided doses, while pramipexole dihydrochloride is
available as immediate release in the dosage range of 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg and extended
release oral tablet in the dosage range of 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg. In the present study,
50 mg/mL for amantadine hydrochloride and 1 mg/mL for pramipexole dihydrochloride was used.
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While most studies using microneedles for transdermal drug delivery have reported flux
enhancement [56,57], there are some studies that have reported lack of flux enhancement [58].
A recent study by Vitorino et al. did not observe significant transdermal flux enhancement after
application of microneedles. Their results showed that the application of a microneedle device as
pretreatment led only to a slight but not statistically significant increase in the transdermal permeation
rate of olanzapine and simvastatin. Their findings suggested that the use of a nanostructured lipid
carrier might have a greater impact on skin permeation than the active enhancement strategy of
microneedle application [27].
Furthermore, it may be possible that the low diffusion coefficient of the drugs may have led to the
lower flux values. Equation 2 shows that there is a relationship between surface area, membrane
thickness, partition coefficient, and diffusion coefficient [59,60].
=

ℎ

(2)

This equation is derived from Fick’s first law of diffusion [59] and describes steady state flux across
membranes. The equation describes the rate of drug flux Jss of the diffusing agent through unit area A
of the membrane as being proportional to the velocity of molecular movement though the diffusional
medium or diffusion coefficient D and to the concentration gradient measured across the membrane.
In this equation D is the effective diffusional pathway of the membrane and the vehicle-membrane
partition coefficient K, which may be further defined as the ratio between the concentration of the
permeant in the membrane at the donor-membrane interface and the vehicle in which it is applied (CV).
According to Lane, this equation indicates that increased flux should be achieved by a change in
diffusion coefficient D, partition coefficient K, and applied drug concentration CV. Therefore, the low
diffusion coefficient of the drugs we investigated in this study may have been responsible for the lack
of flux enhancement with microneedles [60].
A further possible explanation for the low flux values may have been the so-called “bed of nails”
effect. Studies such as Yan et al. and Badran et al. evaluated the effect of microneedle length and
density on transdermal drug delivery [16,61]. Yan et al. observed significant enhancement in acyclovir
flux across human epidermal membrane pretreated with microneedle arrays of 400 μm needle length
and 2000 needles/cm2 in needle density, but a lower enhancement of drug flux was observed for the
microneedles with same needle length but a with a higher needle density of 5625 needle/cm2 [61].
Although the applied force on the microneedles was the same per array, this study found that the force
to an individual needle would be smaller for microneedle arrays with higher needle density. This
phenomenon is similar to the “bed of nails” effect, in which there are a sufficient number of sharp nails
on a bed such that the weight distributed among the nails is not sufficient to exert the pressure needed
by each nail to break the skin. Therefore, a lower-density microneedle array would produce a more
effective puncturing of the skin. It is possible that the application method of applying a constant force
on all the microneedle arrays could benefit the low-density microneedles to some extent because there
was more force applied to each single needle for the low-density microneedles.
A similar trend was observed by Badran et al.; this study focused on the use of microneedle rollers
(Dermaroller®) of various lengths ranging from 150, 500, and 1500 μm on drug permeation [16]. This
study found that the use of the medium and shortest microneedle rollers enhanced drug delivery.
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Furthermore, the shortest microneedle roller led to the highest drug deposition in the SC while the
longer microneedle models deposited drugs in the SC in similar (500 μm) or even lower (150 μm)
amounts when analyzed after incubation of the skin. To our knowledge, this is the first time that the
microneedle approach has been proposed for percutaneous transport of amantadine hydrochloride and
pramipexole dihydrochloride. Though several reports exist in the literature regarding the use of
microneedles for transdermal drug delivery, there are still significant challenges. As seen in this
publication and others (Vitorino et al.) the use of enhancement techniques does not always result in
percutaneous flux increases, and so it is neither trivial nor routine to test the effect of microneedles on
transdermal delivery of each drug.
In summary, the results of our study using a stainless steel microneedle roller indicate that the
microneedle roller device can be used to create microchannels in the SC and is theoretically capable of
enhancing in vitro transport of our compounds of interest across the skin. Our ultimate goal is to
increase the flux values for these drugs, and combined techniques with sonophoresis and chemical
penetration enhancers will be explored. It is important to keep in mind that transcutaneous flux is a
complex phenomenon that depends on several factors such as microneedle geometry and the
physiochemical properties of the compound [62].
5. Conclusions
Application of a microneedle roller did not lead to a statistically significant increase in transdermal flux
values for amantadine and pramipexole in this study. The reason may be insufficient increase in diffusion
coefficient. Our future studies will examine combined techniques such as microneedles in conjunction with
sonophoresis or chemical permeation enhancers as a means of increasing transdermal flux.
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Glossary
Burst force, the peak force which the probe detected as it moved into the sample; Distance to burst,
the distance from the start of the probe touching the sample to the peak force the probe detected (where
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the probe penetrated the tissue); Work to burst, the area under curve from the start of the probe
touching the sample to the peak force; Initial gradient (N/s), the slope of the line from 1% of maximum
force to 20% of maximum force; Mid gradient, slope of the line from 40% to 60% of maximum force;
Final gradient, slope of the line from 80% to 99% of maximum force.
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